查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968647

孤兒藥市場分析及預測（至2035年）：類型、產品類型、技術、應用、最終用戶、服務、流程、實施模式、功能與發展階段

Orphan Drug Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Services, Process, Deployment, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 373 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

孤兒藥市場預計將從2024年的3,734億美元成長到2034年的8,774億美元，年複合成長率約為8.9%。孤兒藥市場涵蓋了針對罕見疾病（影響人群比例較小）而開發的藥物。這些藥物受益於市場獨佔權和稅額扣抵等激勵措施，從而鼓勵創新，儘管患者群體有限。公眾意識的提高和監管支持正在推動市場成長，而生物技術和個人化醫療的進步則正在拓展針對未充分治療疾病的治療前景。

受針對罕見疾病治療方法需求不斷成長的推動，罕見疾病治療市場持續穩定擴張。腫瘤學領域在該市場中成長最為迅猛，這主要得益於罕見癌症發生率的上升和創新藥物的研發。血液學領域緊隨其後，在血液相關疾病的治療方面取得了顯著進展。神經學領域也呈現成長勢頭，反映了罕見神經系統疾病治療方法的進步。生物製藥細分市場，包括單株抗體和基因療法，提供標靶治療方案，是表現最強勁的細分市場。小分子藥物以其易於給藥和生產而著稱，是成長第二快的細分市場。對個人化醫療和精準醫療的日益重視進一步加速了市場動態。製藥公司之間的策略聯盟和夥伴關係正在加強藥物開發平臺。市場獨佔權和加速核准等監管激勵措施在促進創新方面發揮重要作用。人們對罕見疾病的認知不斷提高以及診斷能力的提升也推動了市場成長。

市場區隔
類型 生物製藥、小分子藥物、基因療法、細胞療法、單株抗體、疫苗、酵素替代療法
產品 藥品、生物藥品、先進醫療設備、罕見疾病醫療設備
科技 重組DNA技術、融合瘤技術、基因改造技術、基因編輯、奈米技術
應用領域 腫瘤科、代謝性疾病、神經系統疾病、血液系統疾病、感染疾病、心血管疾病、呼吸系統疾病、免疫系統疾病
最終用戶 醫院、專科診所、研究機構、製藥公司、生技公司、受託研究機構、學術機構
服務 監管服務、臨床試驗服務、諮詢服務、生產服務、分銷服務、上市後監測
過程 臨床開發、監管核准、生產製造、商業化和核准後監測
部署表 內部架構、外包、合作夥伴關係
功能 治療、診斷與預防
步 臨床前研究、I期臨床試驗、II期臨床試驗、III期臨床試驗、IV期臨床試驗

市場概況：

孤兒藥市場正經歷動態變化，其特徵是市場佔有率穩健且定價策略不斷演變。頻繁的新產品上市反映了業界致力於解決罕見疾病問題的決心。市場由具有顯著臨床效益的創新治療方法所驅動，從而催生了高價定價模式。策略合作和收購塑造了競爭格局，推動了市場滲透。北美仍處於領先地位，歐洲和亞太地區也展現出巨大的成長潛力。孤兒藥市場競爭激烈，各大製藥公司競相爭取主導。監管影響至關重要，美國食品藥物管理局管理局 (FDA) 和歐洲藥品管理局 (EMA) 提供市場獨佔權和稅額扣抵等激勵措施。這種法規結構鼓勵研發，並創造了競爭環境。新興市場在政府政策支援和醫療基礎設施不斷完善的推動下，投資正在增加。隨著生物技術和個人化醫療的進步為新的治療方案鋪平道路，孤兒藥市場的未來前景光明。

主要趨勢和促進因素：

罕見病患病率的不斷上升以及政府有利的監管政策推動了孤兒藥市場的顯著成長。關鍵趨勢包括加快藥物核准速度和增加研發經費，這些都促進了藥物研發的創新。製藥公司與研究機構之間合作的加強也進一步支持了市場擴張。此外，生物技術和基因組學的進步使得開發更具標靶性和療效的孤兒藥候選藥物成為可能。醫療專業人員和患者對罕見疾病的認知不斷提高，推動了市場需求。世界各國政府都在提供稅收減免和市場獨佔權等獎勵，以促進孤兒藥的研發。個人化醫療領域正在湧現新的機遇，該領域根據個人基因譜量身訂做治療方案。專注於創新治療方法和策略合作的公司預計將獲得市場佔有率。對以患者為中心的理念和監管支持的日益重視預計將保持市場成長勢頭，尤其是在需求尚未滿足的地區。

限制與挑戰：

孤兒藥市場面臨許多直接限制和挑戰。其中一個主要挑戰是藥物研發高成本，這成為中小型藥廠進入該領域的障礙。這種經濟負擔往往限制了競爭，推高了藥品價格，影響了病人的用藥。此外，監管障礙也導致核准流程延誤。對臨床試驗和安全性評估的嚴格要求會延長核准時間並增加成本。另一個挑戰是招募罕見疾病臨床試驗患者困難。此外，醫護人員和患者對罕見疾病的認知和了解有限，也阻礙了診斷和治療。市場規模有限也抑制了投資，因為與常見疾病相比，投資報酬率通常較低。這些因素共同限制了孤兒藥市場的成長與發展。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 生物製藥
    • 小分子藥物
    • 基因治療
    • 細胞療法
    • 單株抗體
    • 疫苗
    • 酵素替代療法
  • 市場規模及預測：依產品分類
    • 製藥
    • 生物製藥
    • 先進藥物
    • 罕見疾病醫療設備
  • 市場規模及預測：依技術分類
    • 重組DNA技術
    • 融合瘤技術
    • 基因改造技術
    • 基因編輯
    • 奈米科技
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 代謝性疾病
    • 神經系統疾病
    • 血液疾病
    • 感染疾病
    • 心血管疾病
    • 呼吸系統疾病
    • 免疫疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究所
    • 製藥公司
    • 生技公司
    • 合約研究機構
    • 學術機構
  • 市場規模及預測：依服務分類
    • 監管服務
    • 臨床試驗服務
    • 諮詢服務
    • 製造服務
    • 分銷服務
    • 上市後監測
  • 市場規模及預測：依製程分類
    • 臨床開發
    • 監管部門核准
    • 製造業
    • 商業化
    • 核准後監測
  • 市場規模及預測：依發展狀況
    • 內部開發
    • 外包
    • 合作夥伴關係
  • 市場規模及預測：依功能分類
    • 按治療領域
    • 診斷試劑
    • 預防
  • 市場規模及預測：依發展階段分類
    • 臨床前階段
    • I期試驗
    • 第二階段
    • III期臨床試驗
    • IV期試驗

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Alexion Pharmaceuticals
  • BioMarin Pharmaceutical
  • Jazz Pharmaceuticals
  • Ipsen
  • Sarepta Therapeutics
  • Vertex Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • PTC Therapeutics
  • Amicus Therapeutics
  • Prothena Corporation
  • Genmab
  • Orchard Therapeutics
  • uniQure
  • Ascendis Pharma
  • Blueprint Medicines

第9章：關於我們

簡介目錄
Product Code: GIS34113

Orphan Drug Market is anticipated to expand from $373.4 billion in 2024 to $877.4 billion by 2034, growing at a CAGR of approximately 8.9%. The Orphan Drug Market encompasses pharmaceuticals developed for rare diseases, affecting a small percentage of the population. These drugs benefit from incentives like market exclusivity and tax credits, fostering innovation despite limited patient numbers. Rising awareness and regulatory support are propelling growth, with advancements in biotechnology and personalized medicine enhancing therapeutic prospects for underserved conditions.

The Orphan Drug Market is experiencing robust expansion, propelled by increasing demand for treatments targeting rare diseases. Within this market, the oncology segment stands out as the top performer, driven by the rising prevalence of rare cancers and innovative drug developments. Hematology follows closely, with significant advancements in treating blood-related disorders. Neurology is also gaining momentum, reflecting advancements in therapies for rare neurological conditions. The biologics sub-segment, encompassing monoclonal antibodies and gene therapies, leads in performance, offering targeted treatment solutions. Small molecule drugs, known for their ease of administration and production, represent the second-highest performing sub-segment. The growing focus on personalized medicine and precision therapies is further fueling market dynamics. Strategic collaborations and partnerships among pharmaceutical companies are enhancing drug development pipelines. Regulatory incentives, including market exclusivity and reduced approval timelines, play a crucial role in encouraging innovation. The increasing awareness of rare diseases and improved diagnostic capabilities are also contributing to market growth.

Market Segmentation
TypeBiologics, Small Molecules, Gene Therapy, Cell Therapy, Monoclonal Antibodies, Vaccines, Enzyme Replacement Therapies
ProductPharmaceuticals, Biopharmaceuticals, Advanced Therapy Medicinal Products, Orphan Medical Devices
TechnologyRecombinant DNA Technology, Hybridoma Technology, Transgenic Technology, Gene Editing, Nanotechnology
ApplicationOncology, Metabolic Disorders, Neurological Disorders, Hematologic Disorders, Infectious Diseases, Cardiovascular Diseases, Respiratory Diseases, Immunological Disorders
End UserHospitals, Specialty Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutions
ServicesRegulatory Services, Clinical Trial Services, Consulting Services, Manufacturing Services, Distribution Services, Post-Market Surveillance
ProcessClinical Development, Regulatory Approval, Manufacturing, Commercialization, Post-Approval Monitoring
DeploymentIn-House, Outsourced, Collaborative Partnerships
FunctionalityTherapeutic, Diagnostic, Prophylactic
StagePreclinical, Phase I, Phase II, Phase III, Phase IV

Market Snapshot:

The orphan drug market is experiencing a dynamic shift, characterized by a robust market share and evolving pricing strategies. New product launches are frequent, reflecting the industry's commitment to addressing rare diseases. The market is driven by innovative therapies that offer substantial clinical benefits, leading to premium pricing models. The competitive landscape is shaped by strategic collaborations and acquisitions, enhancing market penetration. North America remains at the forefront, with Europe and Asia-Pacific showing significant growth potential. Competition in the orphan drug market is intense, with leading pharmaceutical companies vying for dominance. Regulatory influences play a critical role, with the FDA and EMA providing incentives such as market exclusivity and tax credits. These regulatory frameworks encourage research and development, fostering a competitive environment. Emerging markets are witnessing increased investment, driven by favorable government policies and growing healthcare infrastructure. The market's future is promising, with advancements in biotechnology and personalized medicine paving the way for novel therapeutic solutions.

Geographical Overview:

The orphan drug market is witnessing robust growth across various regions, each with unique characteristics. North America remains dominant, driven by a favorable regulatory environment and significant investments in rare disease research. The region's focus on innovation and supportive policies accelerates market expansion. Europe follows suit, with strong emphasis on healthcare advancements and government incentives fostering a thriving orphan drug ecosystem. The European Union's commitment to rare disease treatment further bolsters market dynamics. In Asia Pacific, the market is burgeoning due to rising healthcare expenditure and increasing awareness of rare diseases. Countries like China and Japan are emerging as key players, investing heavily in research and development. Latin America and the Middle East & Africa are also gaining traction. Brazil and Saudi Arabia are recognizing the potential of orphan drugs, investing in healthcare infrastructure and regulatory frameworks. These regions present new growth pockets, offering lucrative opportunities for market expansion.

Key Trends and Drivers:

The Orphan Drug Market is experiencing substantial growth driven by increasing prevalence of rare diseases and favorable government regulations. Key trends include accelerated drug approvals and enhanced research funding, which are fostering innovation in drug development. The rise in collaborations between pharmaceutical companies and research institutions is further propelling market expansion. Additionally, advancements in biotechnology and genomics are enabling the creation of more targeted and effective orphan drugs. The increasing awareness of rare diseases among healthcare professionals and patients is driving demand. Governments worldwide are offering incentives such as tax credits and market exclusivity to encourage orphan drug development. Opportunities are emerging in personalized medicine, where treatments are tailored to individual genetic profiles. Companies focusing on innovative therapies and strategic partnerships are well-positioned to capture market share. The growing emphasis on patient-centric approaches and regulatory support is poised to sustain market momentum, particularly in regions with unmet medical needs.

Restraints and Challenges:

The orphan drug market encounters several pressing restraints and challenges. One significant challenge is the high cost of drug development, which poses a barrier to entry for smaller pharmaceutical companies. This financial burden often results in limited competition and higher drug prices, affecting accessibility for patients. Additionally, regulatory hurdles create delays in the approval process. The stringent requirements for clinical trials and safety evaluations can extend timelines and increase costs. Furthermore, the market faces challenges in patient recruitment for clinical trials, given the rarity of the diseases targeted by orphan drugs. Moreover, there is a lack of awareness and understanding among healthcare providers and patients about orphan diseases, which hampers diagnosis and treatment. Limited market size also discourages investment, as the potential return on investment is perceived as lower compared to more prevalent conditions. These factors collectively constrain the growth and advancement of the orphan drug market.

Key Players:

Alexion Pharmaceuticals, BioMarin Pharmaceutical, Jazz Pharmaceuticals, Ipsen, Sarepta Therapeutics, Vertex Pharmaceuticals, Ultragenyx Pharmaceutical, PTC Therapeutics, Amicus Therapeutics, Prothena Corporation, Genmab, Orchard Therapeutics, uniQure, Ascendis Pharma, Blueprint Medicines

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Services
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Biologics
    • 4.1.2 Small Molecules
    • 4.1.3 Gene Therapy
    • 4.1.4 Cell Therapy
    • 4.1.5 Monoclonal Antibodies
    • 4.1.6 Vaccines
    • 4.1.7 Enzyme Replacement Therapies
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Biopharmaceuticals
    • 4.2.3 Advanced Therapy Medicinal Products
    • 4.2.4 Orphan Medical Devices
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant DNA Technology
    • 4.3.2 Hybridoma Technology
    • 4.3.3 Transgenic Technology
    • 4.3.4 Gene Editing
    • 4.3.5 Nanotechnology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Metabolic Disorders
    • 4.4.3 Neurological Disorders
    • 4.4.4 Hematologic Disorders
    • 4.4.5 Infectious Diseases
    • 4.4.6 Cardiovascular Diseases
    • 4.4.7 Respiratory Diseases
    • 4.4.8 Immunological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Pharmaceutical Companies
    • 4.5.5 Biotechnology Companies
    • 4.5.6 Contract Research Organizations
    • 4.5.7 Academic Institutions
  • 4.6 Market Size & Forecast by Services (2020-2035)
    • 4.6.1 Regulatory Services
    • 4.6.2 Clinical Trial Services
    • 4.6.3 Consulting Services
    • 4.6.4 Manufacturing Services
    • 4.6.5 Distribution Services
    • 4.6.6 Post-Market Surveillance
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Clinical Development
    • 4.7.2 Regulatory Approval
    • 4.7.3 Manufacturing
    • 4.7.4 Commercialization
    • 4.7.5 Post-Approval Monitoring
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-House
    • 4.8.2 Outsourced
    • 4.8.3 Collaborative Partnerships
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Therapeutic
    • 4.9.2 Diagnostic
    • 4.9.3 Prophylactic
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Preclinical
    • 4.10.2 Phase I
    • 4.10.3 Phase II
    • 4.10.4 Phase III
    • 4.10.5 Phase IV

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Services
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Services
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Services
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Services
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Services
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Services
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Services
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Services
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Services
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Services
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Services
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Services
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Services
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Services
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Services
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Services
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Services
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Services
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Services
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Services
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Services
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Services
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Services
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Services
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Alexion Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 BioMarin Pharmaceutical
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Jazz Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Ipsen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sarepta Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vertex Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Ultragenyx Pharmaceutical
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 PTC Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Amicus Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Prothena Corporation
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Genmab
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Orchard Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 uniQure
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Ascendis Pharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Blueprint Medicines
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us